BioJerusalem BioJerusalem
Jerusalem Life Science Bulletin - Highlights of Jerusalem's Life Science Industry Q3 2011
Dear Friends,

It is with great pleasure that we present to you the third 2011 quarterly issue of the Jerusalem Life Science Bulletin, highlighting the latest achievements and news of Jerusalem's life science cluster.
In July, we had the pleasure of hosting a delegation from San Antonio, led by Mayor Julián Castro and including Ann Stevens, President of Biomed SA, San Antonio’s biomed initiative. As America's seventh largest city, San Antonio is a regional hub for medical care and one of the nation's bioscience leaders in key disease areas including diabetes, military and regenerative medicine, the neurosciences, cancer, and infectious diseases, among others. A collaboration agreement was signed between Biomed SA, and Biojerusalem and we are currently working on the its implementation to bring about our vision of mutual benefit to both regions.

In September BioJerusalem took part in an Entrepreneurship Symposium organized by Bioabroad. The Symposium took place in three major U.S life sciences hubs; Boston, Washington D.C. and San Francisco. The purpose of the Symposium was to meet with entrepreneurs who are interested in establishing their businesses in Israel and to provide them with all of the relevant information. Alongside BioJerusalem, the panel of experts included representatives from the Ministry of Industry, Trade and Labor, the Ministry of Immigration Absorption, and Tax and Legal experts.

The Jerusalem Biomed sector was chosen as the focus of The Jerusalem Economic Forum hosted by Jerusalem Mayor, Nir Barkat. The forum convenes several times per year, focusing each time on a topic of relevance to the city’s economic development. I would like to thank our panel members, Dr. Aharon Schwartz, Prof. Shlomo Mor-Yosef and Prof. Ariel Darvasi, for a very interesting panel discussion.

With best wishes,
Chen Levin, Executive Director of BioJerusalem,
The Jerusalem Development Authority

Clinical & Regulatory News

BioLineRx Announces First Subject Enrolled in Phase I Clinical Trial of BL-1021 for Neuropathic Pain
The primary endpoints of the study are to examine the safety and tolerability of a single administration or multiple administrations of BL-1021

Intec Pharma jumps on positive Parkinson's results
The company's Levodopa accordion pill was found to greatly improve current versions of the drug

BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain
Results show the drug is safe and well tolerated

FDA approves Teva's Jerusalem facility
A new inspection of the Oral Solid Dosage facility found that it complied with current Good Manufacturing Practices

Scientific/Medical Discoveries & Breakthroughs

Yissum Introduces Novel Markers for Brain Cancer Survival Prognosis and a New Treatment Method for the Disease
Findings were published in the prestigious Cancer Research journal

Path to cure for diabetes opens
Glucose-sensing enzyme holds the key to insulin production

Collaborations & Alliances

BioMed SA strikes deal with BioJerusalem
San Antonio mayor, BioMed SA president co-sign memorandum of intent with Jerusalem Development Authority initiative to begin building relationships to benefit biomedical sectors of both regions

Hebrew University's Yissum teams with Shaare Zedek Hospital
Yissum CEO Yaacov Michlin: We'll be the only commercialization company in Israel that works for both a university and a hospital

BioMarCare Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc.
BioMarCare and Ariadne Inc. will jointly develop a diagnostic test

BioLineRx In-Licenses BL-7050
A Novel, Orally-Available Molecule for the Treatment of Neuropathic and Inflammatory Pain

Profiles

Hadasit launches Jewish-Arab biomed incubator in Galilee
Hadasit has pledged to invest NIS 7.5 million in Ways over the next five years

"Large drug companies are stuck in a rut"
Teva's new VC fund head Dr. Aharon Schwartz tells "Globes" about changing trends in drug development

Financial News

BioLineRx Announces Plans to Launch ADR Program on NASDAQ
BioLineRx to list shares through American Depositary Receipts

BioLineRx ADRs Issues
Begin Trading on NASDAQ

Chief Scientist approves NIS 5.9m Biocancell pancreatic cancer trial
The FDA has approved a Phase IIb clinical trial (multicenter efficacy trial) of the BC-819 drug for the treatment of pancreatic cancer

Intec Pharma raises NIS 10.8m in rights issue
The company, which develops improved versions of current drugs, received orders for 99.96% of the units offered

 
Jerusalem Development Authority
This newsletter is brought to you by BioJerusalem, an initiative of the Jerusalem Development Authority, committed to building a strong life science industry in Jerusalem.
Please visit www.biojerusalem.org.il or contact us for more information on how BioJerusalem can assist your business.

In This Issue
Coming Up

WCASI 2011: World Congress for the Advancement of Surgery in Israel
Nov 13-17, 2011

The 11th International Dead Sea Symposium (IDSS 2012) on Cardiac Arrhythmias and Device Therapy
Feb. 26-29, 2012

The International Conference on Integrative Medicine
May 13-15, 2012

New In Jerusalem
The "Marom" Program will come into effect in 2012 and will offer new and improved financial incentives for Biomed companies in Jerusalem. Contact us for additional information.

Financial Incentives for Biomed Companies
Companies located in Jerusalem can benefit from significant governmental and municipal financial support. More

Visit BioJerusalem's Database
BioJerusalem’s free online database is the most comprehensive source of information on life sciences in Jerusalem, including life science companies, academic research and medical institutions, scientists and their research, technology transfer companies, research facilities and equipment, technology parks and incubators, government and local authorities and service providers.
Search database

For Previous issues of the Life Science Bulletin Click here.

Contact Us
BioJerusalem
High Tech Village, Bldg. 1-1
Edmond Safra Campus
Givat Ram, P.O.Box 39026
Jerusalem 91390, Israel

Phone: 972-2-5617532
Email: info@biojerusalem.org.il
For more information on the latest life science activities in Jerusalem and how BioJerusalem can assist your business, visit us at www.biojerusalem.org.il or contact Chen Levin, Executive Director, BioJerusalem, the Jerusalem Development Authority at chen@biojerusalem.org.il.

If you no longer wish to receive the Jerusalem Life Science Bulletin, please unsubscribe
by replying to this email with the word 'remove' in your email message subject line.